Schedule of Events

Why should you attend? Watch the video from Planning Committee member Dustin Boothe, MD, with Intermountain Healthcare as he shares why you won't want to miss this meeting!

View the 2026 Multidisciplinary Radiopharmaceutical Therapy Symposium schedule.

February 16, 2026

4:00 p.m. - 6:00 p.m.

Registration Open
South Registration Counter

February 17, 2026

7:00 a.m. - 4:15 p.m.	Registration Open South Registration Counter
7:00 a.m. - 7:40 a.m.	Continental Breakfast Springs Ballroom G
7:40 a.m. - 7:45 a.m.	Day One Welcome Address Springs Ballroom F Speaker: Jeff Michalski, MD, MBA, FASTRO, Washington University of St. Louis
7:45 a.m. - 8:15 a.m.	Keynote Springs Ballroom F Speaker: Stephen M. Hahn, MD, Nucleus RadioPharma
8:15 a.m. - 9:15 a.m.	Session I: Radiopharmaceutical Program Justification and Initial Start-up Springs Ballroom F Moderator: Ramji R. Rajendran, MD, PhD, Radiation Oncology Consultants Ltd Why Now is the Time to Build a Radiopharmaceutical Therapy Practice Dustin L. Boothe, MD, Intermountain Health Space Requirements for RPT Administration J. Travis Mendel, MD, Rio Grande Cancer Specialists The RAM License and SOP Development Ashley Cockerham, MSJ, Mercurie Consulting, LLC Clinic and Staffing Needs for RPT Delivery Brett E. Lewis, MD, PhD, Hackensack University Medical Center
9:15 a.m. - 10:00 a.m.	Keynote: Radiopharmaceutical Impact Review: Patients, Performance, Potential and People Springs Ballroom F Speaker: Johannes Czernin, MD, University of California
10:00 a.m. - 10:30 a.m.	Coffee Break and Poster Browsing in the Exhibit Hall Springs Ballroom G
10:30 a.m. - 11:30 a.m.	Session II: Authorized User Pathways and Physicist Training in Radiopharmaceutical Therapy Springs Ballroom F Moderator: Xinxin Zhang, PhD, Rutgers Cancer Institute of New Jersey/Robert Wood Johnson University Hospital The Path to Authorized User for Unsealed Byproduct Material Robert J. Tokarz, MS, DABR, RJ Tokarz Medical Imaging Radiation Safety Corp Physicist Training in RPT: The Beginnings of Structured Programs Robert Hobbs PhD, DABR, Johns Hopkins University QA and QC for Dose Calibrators, SPECT/CT and PET/CT Systems for Radiopharmaceutical Therapy John Sunderland, PhD, MBA, The University of Iowa
11:30 a.m. - 12:00 p.m.	Session III: Radiopharmaceutical Therapy Administration and the Role of the QMP Springs Ballroom F Moderator: Jacqueline E. Zoberi, PhD, Washington University of St. Louis Panel Session on RPT Administration and the Role of the QMP Jacqueline E. Zoberi, PhD, Washington University of St. Louis and Joseph G. Dise, MMP, AstraZeneca
12:00 p.m. - 12:30 p.m.	Session IV: Access to Therapy and Addressing Unmet Needs Springs Ballroom F Moderator: Jeffrey Y.C. Wong, MD, FASTRO, City of Hope Increasing Access to Radiopharmaceutical Therapy  Phillip Koo, MD, Prostate Cancer Foundation Addressing Unmet Needs in Radiopharmaceutical Therapy  Ravi Bhasker Patel, MD, PhD, University of Pittsburgh Medical Center
12:30 p.m. - 1:30 p.m.	Lunch and Poster Browsing in the Exhibit Hall Springs Ballroom G
1:30 p.m. - 3:00 p.m.	Plenary Session I Springs Ballroom F Safety and Efficacy of Lu-177 PSMA-617 Versus Established Therapies in mCRPC: Pooled Evidence from Randomized Phase II/III Trials Mohammad Arfat Ganiyani, Department of Medical Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL Quantitative Ra-223 SPECT/CT for Tumor Dosimetry in Combined SBRT–RPT: Retrospective Analysis from a Phase II Trial David Adam, PhD, MS, Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore Phase I Trial Combining Radiopharmaceutical Therapy (RPT) with Total Marrow and Lymphoid Irradiation (TMLI) in Relapsed or Refractory (R/R) AML Jeffrey Wong, MD, FASTRO, Department of Radiation Oncology, City of Hope National Medical Center, Duarte, California Personalized Multi-Timepoint Voxel-Level Dosimetry in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617 Therapy Mustafa Basree, DO, MS, Department of Human Oncology, University of Wisconsin Hospitals and Clinics, Madison, Wisconsin Patient-Specific Dosimetry-Based Approaches of I-131 Therapy of Metastatic Cancer Robert Hobbs, PhD, DABR, FAAPM, Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore 64Cu-Anti-CEA M5A PET Imaging Pre and Post Neoadjuvant Radiotherapy in Advanced Rectal Cancer Jeffrey Wong, MD, FASTRO, Department of Radiation Oncology, City of Hope National Medical Center, Duarte, California Factors Influencing Lesion-Level Response after Lu-177 PSMA-Radioligand Therapy on Post-Therapy SPECT/CT with AI Annotation Gowtham Murugesan, PhD, BAMF Health, Grand Rapids, Michigan Hematologic Toxicity Outcomes of Lu-PSMA-617 in Patients Previously Treated with EBRT for Oligometastatic Disease Daniel Rosen, MD, PhD, Department of Radiation Oncology, Brigham and Women’s / Dana-Farber Cancer Center, Harvard Medical School, Boston Clinical Outcomes among Patients Treated with Lu-PSMA-617 and EBRT for Oligometastatic Prostate Cancer Mai Anh Huynh, MD, PhD, Department of Radiation Oncology, Brigham and Women’s / Dana-Farber Cancer Center, Harvard Medical School, Boston
3:00 p.m. - 4:15 p.m.	Session V: Building Beyond Initial Theranostics: Optimizing Operations, Coordination and Outcomes Springs Ballroom F Moderator: Arpit Michael Chhabra, MD, Bridge Oncology, New York Proton Center, Mt. Sinai Health System Revenue Cycle Management and Prior Authorization Challenges in Theranostics Programs Adam Brown, MBA, NMTCB, Integrated Theranostics Solutions Multidisciplinary Care Coordination Across Referring Providers Munir Ghesani, MD, United Theranostics Workflow Optimization: Software Utilization and Tracking Systems Erik Mittra, MD, PhD, Oregon Health and Science University Clinical Trials Development in Theranostics Programs: Practical Considerations Adam Brown, MBA, NMTCB, Integrated Theranostics Solutions
4:15 p.m. - 5:30 p.m.	Poster Session and Networking in the Exhibit Hall Springs Ballroom G

February 18, 2026

7:00 a.m. - 3:00 p.m.	Registration Open South Registration Counter
7:00 a.m. - 8:00 a.m.	Continental Breakfast Springs Ballroom G
8:00 a.m. - 8:15 a.m.	Day Two Welcome Address Springs Ballroom F Speaker: Vivek S. Kavadi, MD, MBA, FASTRO, ASTRO
8:15 a.m. - 9:15 a.m.	Session VI: Experiences in Collaboration: A Tale of 3 Institutions Springs Ballroom F Moderator: Erin Grady, MD, Stanford University The Penn Medicine Experience Neil Kanth Taunk, MD, MS, Unversity of Pennsylvania Philipose G. Mulugeta, MD, University of Pennsylvania The Intermountain Health Experience Dustin L. Boothe, MD, Intermountain Health Eric Hu, MD, MBA, MPH, Intermountain Health Clinic The Stanford Experience Erin Grady, MD, Stanford University Mallika Marar, MD, MBA, Stanford University
9:15 a.m. - 10:00 a.m.	Session VII: Unique Challenges with Clinical Trials for Radiopharmaceutical Therapy Springs Ballroom F Moderator: Jeff Michalski, MD, MBA, FASTRO, Washington University of St. Louis RPT Clinical Trials — An Investigator and Drug Development Perspective Scott T. Tagawa, MD, New York-Presbyterian Hospital/Weill Cornell Medical Center RPT Trial Challenges in the National Clinical Trials Network Jonathan E. McConathy, MD, The University of Alabama at Birmingham Industry Perspective and Regulatory Challenges for RPT Clinical Trials Michael Morris, MD, Memorial Sloan Kettering Cancer Center
10:00 a.m. - 10:30 a.m.	Coffee Break and Poster Browsing in the Exhibit Hall Springs Ballroom G
10:30 a.m. - 11:30 a.m.	Session VIII: Clinical Challenges in Radiopharmaceutical Therapy Springs Ballroom F Moderator: Ana P. Kiess, MD, PhD, Johns Hopkins Infusion Troubleshooting and Radiation Safety Challenges with RPT Hyun Kim, MD, City of Hope Navigating Hematologic and Renal Dysfunction in RPT for Prostate Cancer Russell Szmulewitz, MD, University of Chicago When Should We Stop or Pause Treatment with RPT? Ana P. Kiess, MD, PhD, Johns Hopkins
11:30 a.m. - 12:30 p.m.	Session IX: Looking to the Future: Novel Targets Springs Ballroom F Moderator: Neil Kanth Taunk, MD, MS, University of Pennsylvania Noval Cancer-Specific Targets in Theranostics Freddy Escorcia, MD, PhD, RayzeBio Pan-cancer Targets in Theranostics Elcin Zan, MD, Cleveland Clinic The Potential and Challenges in Alpha Therapy Implementation Suzanne Lapi, PhD, The University of Alabama at Birmingham
12:30 p.m. - 1:30 p.m.	Lunch and Poster Browsing in the Exhibit Hall Springs Ballroom G
1:30 p.m. - 3:00 p.m.	Plenary Session II Springs Ballroom F Toward Consensus in Lu-177 RPT Dosimetry: Comparing Multi-Timepoint and Single-Timepoint Imaging in Clinical Implementation Siju George, PhD, Herbert Wertheim College of Medicine, Florida International University, Miami Multispecialty Expansion in Radiopharmaceutical Therapy: National Trends in Medicare From 2013–2023 Sean Maroongroge, MD, MBA, Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA Development and Implementation of an Internal Dosimetry Program to Evaluate Radiotoxicity in Patients Treated with Sequential Lu-177-PSMA and Ac-225-PSMA Radiopharmaceutical Therapy Serguei Castaneda, MD, CB Oncology Partners, Cutler Bay, FL A Model of Parallel Radiopharmaceutical Therapy Delivery in One Large Academic Health System Seema Kacker, MD, PhD, Johns Hopkins University School of Medicine, Baltimore A Multidisciplinary Care Process Model for Radiopharmaceutical Therapy Including Both Radiation Oncologists and Nuclear Medicine Physicians as Authorized Users Dustin Boothe, MD, Intermountain Health, Salt Lake City Using Virtual Phantoms to Commission the Fitting, Integration, and Dose Calculation for Lu-177 Radiopharmaceutical Therapy Dose Calculations Jose Garcia-Ramirez, MS, WashU Medicine, Department of Radiation Oncology, St. Louis From Concept to Clinic: Development and Prototype Implementation of the Intelligent Radiotherapy Collaboration System for Integrated Radiopharmaceutical Workflows Ranjini Tolakanahalli, PhD, Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami Challenges Establishing a Radiopharmaceutical Therapy Clinic within a Radiation Oncology Department in a Community-Based Hospital Daniel Sforza, PhD, Department of Radiation Oncology and Molecular Radiation Sciences, School of Medicine, Johns Hopkins University, Baltimore Radiopharmaceutical Retreatment Andrew Salner, MD, FASTRO, Hartford HealthCare Cancer Institute, Hartford, CT
3:00 p.m. - 3:45 p.m.	Session X: Current Status and Challenges of Dosimetry Springs Ballroom F Moderator: Robert Hobbs, PhD, DABR, Johns Hopkins Status of RPT Dosimetry Methods and Results Yuni Dewaraja, MS, PhD, University of Michigan QA and Harmonization in RPT
3:45 p.m. - 4:15 p.m.	Coffee Break and Poster Browsing in the Exhibit Hall Springs Ballroom G
4:15 p.m. - 5:00 p.m.	Session XI: Radiobiological and Translational Aspects of RPTs Springs Ballroom F Moderator: Terence M. Williams, MD, PhD, City of Hope The Impact of Dose, Dose Rate, Dose Heterogeneity, and Immuno-Radiobiology and the Translation of RPT Zachary Scott Morris, MD, PhD, University of Wisconsin School of Medicine and Public Health Translating Radiolabeled Antibodies from Bench to Bedside Anna Wu, PhD, City of Hope

American Society for Radiation Oncology
251 18th Street South, 8th Floor
Arlington, VA 22202
Telephone: 703-502-1550
www.astro.org

Attend

Experience

Learn

Exhibit Hall

Exhibitors

Schedule of Events

TERMS OF USE & PRIVACY POLICY

Connect With Us: